Levosimendan: a new option in acute cardiac failure.
Holley
Anthony David
AD
Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia. anthony_holley@health.qld.gov.au
Ziegenfuss
Marc
M
D001682:Biological Availability; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006835:Hydrazones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011724:Pyridazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077464:Simendan
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan